 |
|
|
Important Notice: The Forum does not endorse any medical
product or therapy. ALL medications and supplements
should be taken ONLY under the supervision of a physician,
due to the possibility of side-effects, drug interactions,
etc.
|
Drug:
|
Bifeprunox
|
|
Clinical Trial ID:
|
NCT00366327
|
|
Mode of action:
|
5HT2A & D2 partial agonist
|
|
Phase:
|
Discontinued
|
|
Company:
|
Solvay, Wyeth
|
|
Note:
|
Development halted
|
Cosi C, Carilla-Durand E, Assié MB, Ormiere AM, Maraval M,
Leduc N, Newman-Tancredi A. Partial agonist properties of
the antipsychotics SSR181507, aripiprazole and bifeprunox at
dopamine D2 receptors: G protein activation and prolactin
release. Eur J Pharmacol . 2006 Mar 27 ; 535(1-3):135-44. Abstract
|
|
|
|
|
Text Size 
See our most recent Schizophrenia Bulletin theme Webinar: